Gilead Sciences, Inc. $GILD Shares Acquired by Trust Co. of Vermont

Trust Co. of Vermont increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,976 shares of the biopharmaceutical company’s stock after acquiring an additional 320 shares during the quarter. Trust Co. of Vermont’s holdings in Gilead Sciences were worth $1,328,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Price T Rowe Associates Inc. MD increased its holdings in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new stake in Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in Gilead Sciences in the second quarter valued at about $238,083,000. Los Angeles Capital Management LLC increased its holdings in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on GILD shares. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Royal Bank Of Canada upped their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. Rothschild & Co Redburn upped their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $111.15 on Thursday. Gilead Sciences, Inc. has a 12-month low of $83.10 and a 12-month high of $121.83. The firm has a market capitalization of $137.92 billion, a price-to-earnings ratio of 22.14, a price-to-earnings-growth ratio of 0.75 and a beta of 0.34. The business has a 50 day simple moving average of $114.47 and a 200 day simple moving average of $109.92. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.